AU · rank #7 · 2026-09-10
INSM
NASDAQ · $27.58B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.985 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.67 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 10 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.172 |
| Analyst upside Consensus target $200.18 | +55.4% |
| Momentum acceleration 3-month minus 12-month momentum. | +34.56% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.81 |
| Gross margin TTM | +83.5% |
| 52w high | $212.75 |
| Market cap (USD) | $27.58B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Insmed is a commercial-stage rare/respiratory disease biopharma whose revenue is now dominated by the rapid launch ramp of BRENSOCATIB (BRINSUPRI) for bronchiectasis alongside the established ARIKAYCE franchise.
Rationale
The analyst_upside_pct of 55% is reinforced by a concrete fundamental catalyst — a 91% Q2 EPS beat, raised full-year guidance to $1.25–$1.4B, and 17 analysts with 81% revision agreement all lifting targets — making the Street's bullishness earnings-driven rather than purely sentiment-based.
Material risks
- 1Target price dispersion of 37% (range ~$167–$263) signals high uncertainty around BRINSUPRI's peak sales trajectory; any slowdown in new patient starts or payer coverage friction could rapidly compress the consensus target and unwind the upside thesis.
- 2Zero insider buying over 90 days despite a 55% implied upside gap is a notable divergence — insiders closest to the launch data are not putting capital behind the Street's optimism, which warrants scrutiny.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.